On Friday, Pernix Therapeutics Holdings Inc (NASDAQ:PTX)’s shares inclined 0.21% to $4.70.
Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, declared positive results from Category 1 (in vitro) abuse deterrence studies with ZX007, utilizing Altus Formulation’s proprietary INTELLITABTM abuse deterrent technology platform. ZX007 is an abuse-deterrent, extended-release oral hydrocodone bitartrate formulation product in development for the administration of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. The purpose of the studies was to perform a comprehensive battery of laboratory tests to assess the physical and chemical properties of ZX007. These studies were conducted in accordance with the April 2015 Food and Drug Administration (FDA) Guidance for Industry: Abuse-Deterrent Opioids — Evaluation and Labeling.
Top-line results from the study demonstrated ZX007’s ability to:
- Resist common methods of physical manipulation counting crushing between spoons, crushing in a tablet hardness tester, and crushing in pill crushers;
- Resist alcohol induced dose dumping and prevent drug extraction in a range of common solvents;
- Not yield extracts that could be expelled through syringe needles; and
- Maintain controlled release after crushing and grinding of the tablets under a number of test conditions.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder.
At the end of Friday’s trade, Baytex Energy Corp (USA) (NYSE:BTE)‘s shares dipped -4.58% to $6.88.
Baytex Energy Corp. (BTE) reports that a cash dividend of $0.10 per common share in respect of August operations will be paid on September 15, 2015 to shareholders of record on August 21, 2015. The ex-dividend date is August 19, 2015. This dividend is an eligible dividend for the purposes of the Income Tax Act (Canada).
The U.S. dollar equivalent dividend amount is about US$0.0762 per share assuming a foreign exchange rate of $0.7621 USD/CAD. The actual U.S. dollar equivalent dividend for shareholders who hold through a brokerage firm will be based on the exchange rate in effect on the payment date and net of applicable Canadian withholding taxes. Registered shareholders are paid directly by Baytex’s transfer agent, Valiant Trust Company, and the actual U.S. dollar equivalent dividend will be based on the exchange rate in effect on the record date and paid net of applicable Canadian withholding taxes.
Baytex Energy Corp., an oil and gas company, engages in the acquisition, development, exploitation, and production of oil and natural gas in the Western Canadian Sedimentary Basin and the United States. The company offers heavy oil, light oil, condensate, and natural gas liquids. As of December 31, 2014, it had proved reserves of 283 million barrels of oil equivalent (mmboe); and proved plus probable reserves of 432 mmboe. The company was founded in 1993 and is headquartered in Calgary, Canada.
Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares dropped -0.49% to $6.05.
Keryx Biopharmaceuticals, Inc. (KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, declared its financial results for the second quarter ended June 30, 2015.
BUSINESS HIGHLIGHTS
Auryxia U.S. Commercialization
- Net U.S. Auryxia product sales for the second quarter were about $1.8 million, based on about 3,700 Auryxia prescriptions, as stated to the company by IMS Health and specialty pharmacies that do not report data to IMS, counting DaVita Rx and Fresenius Rx.
- Unrestricted access for Auryxia raised to 65 percent across Medicare Part D and commercial insurance providers, with the addition of Auryxia on the formularies of two national Part D insurance providers that began processing claims in the third quarter of 2015.
- Keryx’s sales representatives have reached more than 75 percent of the 5,000 prescriber targets; about 1,000 target prescribers have written a prescription for Auryxia.
- Keryx successfully introduced samples into the market in the second quarter, with about 6,000 starter kits shipped to about 1,300 target prescribers — the majority of whom had not formerly prescribed Auryxia.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia. Auryxia is also used to control serum phosphorus levels in patients with chronic kidney disease on dialysis.
Baker Hughes Incorporated (NYSE:BHI), ended its Friday’s trading session with 0.79% gain, and closed at $57.35.
Baker Hughes Incorporated (BHI) Chairman and Chief Executive Officer Martin S. Craighead declared recently that the Baker Hughes Board of Directors declared the regular quarterly cash dividend of $0.17 per share of common stock payable September 23, 2015 to holders of record on September 2, 2015.
Baker Hughes Incorporated supplies oilfield services, products, technology, and systems to the oil and natural gas industry worldwide. The company offers drilling and evaluation products and services, which comprise drill bits for performance drilling, hole enlargement, and coring; conventional and rotary steerable systems used to drill wells; measurement-while-drilling and logging-while-drilling systems to perform reservoir navigation services; drilling optimization services; tools for coil tubing drilling and wellbore re-entry systems; coring drilling systems; surface logging; emulsion and water-based drilling fluids systems; reservoir drill-in fluids; and fluids environmental services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
